Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Richard Eek"'
Autor:
Wee Joo Chng, Bradley Augustson, Brian G.M. Durie, Jeffrey Sy. Huang, Hang Quach, Noemi Horvath, Yoon Sung Soo, Kim Ki-Hyun, Jae Hoon Lee, Jane Estell, Je-Jung Lee, Simon J. Harrison, Soo Mee Bang, Rajeev Rajagopal, Philip Campbell, Nichloas Murphy, Richard Eek, Belinda Butcher
Publikováno v:
Blood. 136:39-40
Background: The combination of carfilzomib with immunomodulatory drugs (IMiDs) and dexamethasone is active in multiple myeloma (MM). Carfilzomib, thalidomide, and dexamethasone (KTd) has been studied in upfront MM treatment but has not been studied i
Autor:
Steven Le Gouill, Carlos Panizo, Tadeusz Robak, Michael Wang, Thierry Lamy, Monika Długosz-Danecka, Pier Luigi Zinzani, Bijal D. Shah, Rene-Olivier Casasnovas, Lucie Oberic, Priti Patel, Simon Rule, Richard Eek, Stephen D. Smith, Lin Tao, Gandhi Damaj, Jeanette K. Doorduijn, Andre Goy, Andrew Davies, Preetesh Jain, Franck Morschhauser, Jehan Dupuis, Eric N. Jacobsen, Graham Brock, Arnon P. Kater
Publikováno v:
Blood. 136:38-39
Background: Acalabrutinib (acala) is a next-generation, highly selective, covalent Bruton tyrosine kinase (BTK) inhibitor approved for patients (pts) with mantle cell lymphoma (MCL) who have received ≥1 prior therapy. The efficacy and safety of aca
Autor:
David T Yeung, Andrew Grigg, Naranie Shanmuganathan, Ann Christine Solterbeck, Deborah L. White, Susan Branford, Nicholas Viiala, Philip Arthur Rowlings, Anthony K Mills, Jake Shortt, Campbell Tiley, David M Ross, David Kipp, Rosemary Anne Harrup, Ilona Cunningham, John Kwan, Richard Eek, Howard Mutsando, Ken-Soon Tan, Kate Burbury, Matthew P.F. Wright, Timothy P. Hughes, On Behalf of the ALLG
Publikováno v:
Blood. 134:4150-4150
Dasatinib treatment leads to excellent molecular responses in chronic phase chronic myeloid leukemia (CP-CML). Pleural effusions, an adverse event related dasatinib treatment, may lead to intolerance and drug discontinuations. Strategies aimed at min
Autor:
Ming Yin, Michael Wang, Arnon P. Kater, Tadeusz Robak, Andre Goy, Eric N. Jacobsen, Lucie Oberic, Raquel Izumi, Andrew Davies, Simon Rule, Priti Patel, Richa Dua, Jeanette K. Doorduijn, Thierry Lamy, Melanie M. Frigault, Carlos Panizo, Gandhi Damaj, Wojciech Jurczak, Steven Le Gouill, Stephen D. Smith, Pier Luigi Zinzani, Dorothy Nguyen, Richard Eek, Olivier Casasnovas, Franck Morschhauser, Jehan Dupuis, Bijal D. Shah
Publikováno v:
Blood. 132:2876-2876
Background: Mantle cell lymphoma (MCL), an aggressive B-cell non-Hodgkin lymphoma, remains incurable with standard therapies. The highly selective, potent Bruton tyrosine kinase (BTK) inhibitor acalabrutinib was approved by the US Food and Drug Admin
Autor:
Richard Eek, Stephen P. Mulligan, Nicholas E. Murphy, Bryone J. Kuss, Jane A. Freeman, Xavier Badoux, Constantine S. Tam, Naomi Mackinlay, Ann Solterbeck, Duncan P. Carradice, Gavin Cull, Oliver Giles Best
Publikováno v:
Blood. 132:3144-3144
BACKGROUND The prior Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Study showed dose-reduced oral fludarabine and cyclophosphamide plus rituximab (FCR3) was safe, tolerable and effective in fit elderly patients for front-line therapy for CLL.
Autor:
Bradley Augustson, Belinda Butcher, Wee Joo Chng, Tracey Gerber, Brian G.M. Durie, Nicholas E. Murphy, Richard Eek, Rajeev Rajagopal, Jane Estell, Slavisa Ninkovic, Simon J. Harrison, Hang Quach, Peter Mollee, Noemi Horvath, Philip Campbell, Robyn Hemme, Akash Kalro
Publikováno v:
Blood. 132:1955-1955
Background: Carfilzomib lenalidomide and dexamethasone (KRd) is FDA-approved for the treatment relapsed/refractory multiple myeloma (RRMM) based on data from the ASPIRE study (Stewart K et al. NEJM 2015). Thalidomide, a first generation immunomodulat
Autor:
Cyrille Hulin, Kevin W. Song, Annette Ervin-Haynes, Fritz Offner, Guang Chen, Philippe Rodon, Ulrich Dührsen, Andrew Belch, Shaker R. Dakhil, Hannah Hunter, Isabelle Azais, Maria Teresa Petrucci, Chaim Shustik, Jin Lu, Laurent Garderet, Thierry Facon, Vanessa Houck, Margaret Macro, Richard Eek, Brigitte Pegourie
Publikováno v:
Blood. 124:81-81
Background: In the pivotal FIRST trial, a randomized, international, multicenter phase 3 study, continuous Rd compared with melphalan-prednisone-thalidomide (MPT) improved progression-free survival (PFS) which was the primary endpoint (HR = 0.72; P <